Imaging-defined subclinical atherosclerosis in subclinical hypothyroidism: Prevalence, associated factors, and preventive implications Authors: Arif Albulushi, Murtadha S Hasan, Rayan S Alazawi, Maryam Al Sarmi, Hajar Al-Mandhari, Abdullah AlShaharli, Amjad S Hasan, Yaseen Al-Helli, Abdullah Allo, Eslam Abdelazim, Taghrid Taha, Ahmed Sena, Abdulhakim M Alhazmi, Lama S Alfehaid Published: 2026 ABSTRACT AbstractBackgroundSubclinical hypothyroidism (SCH) has been linked to adverse cardiovascular profiles; however, the burden of subclinical atherosclerosis detected by imaging and its associated drivers remain insufficiently characterized, particularly in real-world Middle Eastern populations.ObjectivesTo quantify the prevalence of imaging-defined subclinical atherosclerosis in adults with SCH and to identify clinical and biochemical factors independently associated with its presence.MethodsWe conducted a cross-sectional study of 500 adults with SCH (TSH 4.5–10 mIU/L with normal free T4) evaluated at a tertiary cardiac center in Oman (December 2023–September 2025). Participants underwent fasting lipid assessment, high-sensitivity C-reactive protein (hs-CRP), carotid ultrasound (carotid plaque and intima–media thickness [CIMT]), and coronary artery calcium (CAC) scoring. The primary outcome was imaging-defined subclinical atherosclerosis, defined as the presence of at least one of the following: CIMT >1.0 mm, carotid plaque, or CAC >100. Multivariable logistic regression was performed using prespecified clinically relevant covariates, including age, sex, body mass index, metabolic syndrome, LDL-C, hs-CRP, and TSH category.ResultsOverall, 46% of patients demonstrated imaging-defined subclinical atherosclerosis. The prevalence of CIMT >1.0 mm, carotid plaque, and CAC >100 was 26%, 29%, and 22%, respectively. Imaging-defined subclinical atherosclerosis was substantially more frequent among individuals with metabolic syndrome (72% vs. 33%, p < 0.001). In adjusted models, LDL-C > 160 mg/dL (OR 2.1, 95% CI 1.5–2.9), hs-CRP >3 mg/L (OR 1.9, 95% CI 1.4–2.5), TSH >7 mIU/L (OR 1.7, 95% CI 1.2–2.3), and metabolic syndrome (OR 2.5, 95% CI 1.8–3.5) were independently associated with imaging-defined subclinical atherosclerosis.ConclusionsNearly half of adults with SCH exhibit imaging evidence of subclinical atherosclerosis. Higher LDL-C, systemic inflammation, higher TSH, and metabolic syndrome identified a subgroup with a disproportionately greater burden of imaging-defined subclinical atherosclerosis. These findings support a more individualized cardiometabolic risk assessment strategy in SCH and justify prospective studies evaluating whether targeted preventive strategies improve long-term outcomes.Keywords: Subclinical hypothyroidism, Subclinical atherosclerosis, Coronary artery calcium, Carotid intima–media thickness, Carotid plaque, Metabolic syndrome, Inflammation, LDL cholesterol Introduction Subclinical hypothyroidism (SCH), characterized by elevated thyroid-stimulating hormone (TSH) levels with preserved circulating free thyroxine (FT4), is among the most frequently encountered endocrine abnormalities in adults, affecting an estimated 4–15% of the general population and occurring more commonly in women and older individuals [1], [2]. Although SCH has historically been viewed as a mild or clinically silent state, contemporary evidence increasingly supports its association with a higher burden of cardiovascular (CV) morbidity and long-term adverse outcomes, challenging the notion that SCH is uniformly benign [3], [4], [5]. The biological pathways linking SCH to cardiovascular risk are multifactorial and incompletely defined, likely reflecting a convergence of metabolic, vascular, and inflammatory disturbances [6], [7]. Several studies have demonstrated that SCH is associated with a more atherogenic lipid profile, particularly higher low-density lipoprotein cholesterol (LDL-C), a central contributor to atherosclerosis initiation and progression and a major determinant of preventable cardiovascular events [8], [9]. Beyond dyslipidemia, systemic inflammation has emerged as a plausible mechanistic bridge between SCH and vascular injury. Inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), have been reported to be elevated in SCH and may mediate endothelial dysfunction, plaque vulnerability, and downstream ischemic events [10], [11]. These mechanisms collectively suggest that SCH may represent a cardiovascular risk-enriched phenotype, particularly in the presence of concurrent metabolic stressors. In recent years, noninvasive imaging markers of subclinical atherosclerosis have become increasingly valuable for refining cardiovascular risk stratification beyond conventional clinical predictors [12], [13], [14]. Carotid intima–media thickness (CIMT) and coronary artery calcium (CAC) scoring are widely validated markers with strong prognostic relevance for future cardiovascular events and mortality, and their incremental value has been demonstrated across diverse risk groups [15], [16]. Despite this, the evidence base specifically addressing the prevalence and clinical significance of CIMT and CAC abnormalities in SCH remains limited and heterogeneous, with inconsistent results across populations and study designs. This gap is clinically meaningful, as imaging-defined atherosclerosis may identify high-risk individuals who would not be recognized using traditional risk factors alone. Importantly, SCH frequently clusters with cardiometabolic comorbidities including obesity, hypertension, diabetes mellitus, and metabolic syndrome—conditions that may amplify vascular injury and accelerate atherosclerosis progression [17], [18], [19]. Metabolic syndrome, in particular, represents a high-risk cardiometabolic state associated with substantial increases in cardiovascular morbidity and mortality, reinforcing the need for integrated cardiovascular assessment in such patients [20]. In this context, SCH may act as an additive or synergistic risk factor, intensifying atherosclerotic burden when combined with adverse metabolic profiles. Despite growing mechanistic and observational evidence, clinical guidance regarding cardiovascular evaluation and management in SCH remains variable, reflecting uncertainty about which patients derive the greatest benefit from targeted risk assessment and preventive strategies [21], [22], [23]. A clearer understanding of the prevalence of subclinical atherosclerosis and its independent predictors in SCH is therefore essential to move toward a more individualized, risk-based approach [24]. Accordingly, this study aimed to evaluate the burden of imaging-defined subclinical atherosclerosis in a well-characterized cohort of adults with subclinical hypothyroidism assessed at a tertiary cardiac center, using carotid ultrasonography and coronary artery calcium scoring. In addition, we sought to identify clinical and biochemical correlates of imaging-positive subclinical atherosclerosis and to examine whether coexisting metabolic syndrome identifies a subgroup with greater atherosclerotic burden [25]. By providing real-world imaging and biomarker-based data, our findings may help refine clinical risk stratification strategies and support earlier, more targeted preventive interventions in this commonly overlooked risk group. Methods Study design and setting We conducted a cross-sectional observational study at the National Heart Centre, Royal Hospital, Muscat, Oman, between December 2023 and September 2025. The study was designed to (1) quantify the prevalence of imaging-defined subclinical atherosclerosis in adults with subclinical hypothyroidism (SCH) and (2) identify clinical and biochemical factors associated with imaging-defined subclinical atherosclerosis. Study population Consecutive adults (≥18 years) referred to the National Heart Centre outpatient endocrinology and cardiology clinics were screened for eligibility. SCH was defined as serum thyroid-stimulating hormone (TSH) 4.5–10 mIU/L with normal free thyroxine (FT4) concentrations, confirmed on laboratory testing. Patients were excluded if they had overt thyroid dysfunction (hypothyroidism or hyperthyroidism), prior or ongoing thyroid hormone replacement or antithyroid therapy, established cardiovascular disease (history of myocardial infarction, stroke, peripheral arterial disease, or prior coronary/peripheral revascularization), chronic kidney disease stage ≥3, significant hepatic dysfunction (defined as alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of normal, total bilirubin >2 times the upper limit of normal, or known chronic liver disease with active biochemical impairment), pregnancy, or incomplete clinical/laboratory datasets. A consecutive recruitment strategy was used to reduce selection bias by enrolling all eligible patients during the study period. Sample size A target sample size of 500 participants was selected a priori to provide adequate precision for estimating the prevalence of imaging-defined subclinical atherosclerosis in SCH. This estimate was based on an expected prevalence of approximately 40%, with a 95% confidence interval and 5% margin of error, while allowing for exclusions and missing data. Study measures and definitions The primary outcome was imaging-defined subclinical atherosclerosis, defined as the presence of at least one of the following imaging abnormalities: carotid intima–media thickness (CIMT) >1.0 mm, carotid plaque, or coronary artery calcium (CAC) score > 100. Because these variables reflect subclinical atherosclerotic burden rather than cardiovascular risk per se, the composite outcome was treated as an imaging-defined atherosclerosis endpoint throughout the analysis. Prespecified clinically relevant covariates included age, sex, body mass index (BMI), smoking status, hypertension, diabetes mellitus, lipid-lowering therapy, TSH category (>7 mIU/L vs. ≤7 mIU/L), LDL-C, hs-CRP, and metabolic syndrome. Because HDL-C is a defining component of metabolic syndrome, it was not included as an independent variable in the multivariable model to avoid conceptual overlap and collinearity. Traditional cardiovascular risk factors were captured at baseline, including hypertension, diabetes mellitus, smoking status, and medication use, based on clinical assessment and electronic records. Hypertension and diabetes were defined by prior diagnosis and/or treatment, consistent with metabolic syndrome criteria. Smoking status was categorized as current, former, or never. Medication use included lipid-lowering, antihypertensive, and glucose-lowering therapies. These variables were examined descriptively and considered in exploratory analyses; however, they were not retained in the primary multivariable model in order to preserve model parsimony and reduce overlap with metabolic syndrome and related cardiometabolic covariates. Metabolic syndrome was defined according to the revised National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria as the presence of ≥3 of the following: abdominal obesity (waist circumference ≥ 102 cm in men or ≥ 88 cm in women), triglycerides ≥150 mg/dL, HDL-C < 40 mg/dL in men or < 50 mg/dL in women, blood pressure ≥ 130/85 mmHg or treatment for hypertension, and fasting glucose ≥100 mg/dL or treatment for diabetes. Clinical, laboratory, and imaging assessment All participants underwent standardized clinical evaluation including demographics, relevant comorbidities, anthropometric measurements (BMI and waist circumference), and blood pressure measurement. Laboratory assessment included fasting lipid profile, fasting glucose, HbA1c, and hs-CRP, performed using routine standardized assays within the institution. Carotid ultrasonography was performed by certified sonographers using high-resolution B-mode imaging. CIMT was measured at the distal common carotid artery using established protocols, and carotid plaque was recorded when present. CIMT >1.0 mm or plaque presence was considered abnormal. CAC scoring was performed using non-contrast cardiac computed tomography on a 64-slice scanner, with CAC quantified using the Agatston method. A CAC score > 100 was prespecified to represent clinically meaningful elevated atherosclerotic burden. This threshold was chosen to reflect a more established and clinically meaningful calcific plaque burden, while recognizing that any CAC >0 may also indicate subclinical coronary atherosclerosis. A sensitivity analysis using CAC >0 as an alternative threshold was also performed. Statistical analysis Continuous variables are presented as mean ± standard deviation or median (interquartile range), as appropriate, and categorical variables as counts and percentages. Participants were compared according to the presence or absence of imaging-defined subclinical atherosclerosis. Between-group comparisons were performed using the independent t-test or Mann–Whitney U test for continuous variables and the chi-square test or Fisher exact test for categorical variables, as appropriate. The primary binary outcome was imaging-defined subclinical atherosclerosis, defined as the presence of CIMT >1.0 mm, carotid plaque, or CAC >100. Multivariable logistic regression was performed using a prespecified clinically relevant model, with covariates selected a priori based on established literature and biological plausibility. The primary model included age, sex, body mass index, metabolic syndrome, LDL-C > 160 mg/dL, hs-CRP >3 mg/L, and TSH >7 mIU/L. Traditional cardiovascular risk factors, including smoking status, hypertension, diabetes mellitus, and lipid-lowering therapy, were evaluated as additional covariates but were not included in the primary model due to collinearity with metabolic syndrome components. Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). Multicollinearity was assessed using the variance inflation factor, with values <5 considered acceptable. Model calibration was evaluated using the Hosmer–Lemeshow goodness-of-fit test. A two-sided p value <0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics version 28.0 (IBM Corp., Armonk, NY, USA). Ethics The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the National Heart Centre, Royal Hospital, Oman. Written informed consent was obtained from all participants prior to enrollment. Results Study population The study flow and derivation of the final analytic cohort are shown in Fig. 1. A total of 500 adults with subclinical hypothyroidism (SCH) were included. The mean age was 54.7 ± 11.3 years, 68% were women, and the mean BMI was 29.2 ± 5.1 kg/m2. Mean TSH was 6.8 ± 1.4 mIU/L, and metabolic syndrome was present in 38% of participants. Baseline characteristics stratified by the presence or absence of imaging-defined subclinical atherosclerosis are summarized in Table 1. Study flow diagram. Table 1Baseline characteristics stratified by imaging-defined subclinical atherosclerosis status.VariableNo Imaging-Defined Subclinical Atherosclerosis (n = 270)Imaging-Defined Subclinical Atherosclerosis Present (n = 230)p-valueAge (years)52.3 ± 11.457.4 ± 10.8<0.001Female sex (%)64%72%0.03BMI (kg/m2)28.1 ± 4.830.4 ± 5.2<0.001TSH (mIU/L)6.5 ± 1.47.1 ± 1.30.002LDL-C (mg/dL)145 ± 18167 ± 15<0.001hs-CRP (mg/L)2.4 ± 0.93.8 ± 1.2<0.001Metabolic syndrome (%)24%55%<0.001 Baseline characteristics stratified by imaging-defined subclinical atherosclerosis status. Prevalence of imaging-defined subclinical atherosclerosis Overall, 46% (n = 230) met criteria for imaging-defined subclinical atherosclerosis, defined by the presence of at least one abnormal imaging marker (CIMT >1.0 mm, carotid plaque, or CAC score > 100). The prevalence of individual abnormalities was 26% for CIMT >1.0 mm, 29% for carotid plaque, and 22% for CAC >100 (Table 2, Fig. 2). Notably, clustering of abnormalities was common, with a substantially higher burden observed in participants with metabolic syndrome (Table 2). Table 2Prevalence of imaging-defined subclinical atherosclerosis overall and by metabolic syndrome status.VariableOverall (n = 500)No Metabolic Syndrome (n = 310)Metabolic Syndrome (n = 190)p-valueCIMT >1.0 mm (%)26%19%38%<0.001Carotid plaque (%)29%18%45%<0.001CAC >100 (%)22%17%41%<0.001Imaging-defined subclinical atherosclerosis (%)46%33%72%<0.001 Prevalence of imaging-defined subclinical atherosclerosis overall and by metabolic syndrome status. Prevalence of individual imaging abnormalities in subclinical hypothyroidism. In a sensitivity analysis using CAC >0 as an alternative coronary calcium threshold, the direction and magnitude of the associations with LDL-C, hs-CRP, TSH >7 mIU/L, and metabolic syndrome were materially unchanged. Risk marker burden according to metabolic syndrome The presence of metabolic syndrome markedly enriched for subclinical atherosclerosis. Among participants with metabolic syndrome, 72% met criteria for imaging-defined subclinical atherosclerosis compared with 33% of those without metabolic syndrome (p < 0.001) (Table 2, Fig. 2). The magnitude of this difference in imaging-defined subclinical atherosclerosis according to metabolic syndrome status is illustrated in Fig. 3. This association was consistent across individual imaging markers, supporting metabolic syndrome as a dominant driver of imaging-defined vascular risk within the SCH population. Association of metabolic syndrome with imaging-defined subclinical atherosclerosis in subclinical hypothyroidism. Clinical and biochemical differences by risk status Compared with participants without imaging-defined subclinical atherosclerosis, those with imaging-positive subclinical atherosclerosis were older (57.4 ± 10.8 vs. 52.3 ± 11.4 years; p < 0.001) and had higher BMI (30.4 ± 5.2 vs. 28.1 ± 4.8 kg/m2; p < 0.001) (Table 1). The imaging-positive group also demonstrated a significantly more adverse cardiometabolic and inflammatory profile, including higher LDL-C (167 ± 15 vs. 145 ± 18 mg/dL; p < 0.001) and higher hs-CRP (3.8 ± 1.2 vs. 2.4 ± 0.9 mg/L; p < 0.001) (Table 2). Although SCH severity was modest overall, TSH levels were slightly but significantly higher among those with imaging-defined subclinical atherosclerosis (7.1 ± 1.3 vs. 6.5 ± 1.4 mIU/L; p = 0.002) (Table 2). Independent predictors of imaging-defined subclinical atherosclerosis In multivariable logistic regression using prespecified clinically relevant covariates, LDL-C > 160 mg/dL, hs-CRP >3 mg/L, TSH >7 mIU/L, and metabolic syndrome remained independently associated with imaging-defined subclinical atherosclerosis (Table 3, Fig. 4). LDL-C > 160 mg/dL was associated with more than double the odds of imaging-defined subclinical atherosclerosis (OR 2.1, 95% CI 1.5–2.9; p < 0.001), and hs-CRP >3 mg/L was also independently associated (OR 1.9, 95% CI 1.4–2.5; p < 0.001). SCH severity, represented by TSH >7 mIU/L, remained a significant predictor after adjustment (OR 1.7, 95% CI 1.2–2.3; p = 0.002). Metabolic syndrome showed the strongest association (OR 2.5, 95% CI 1.8–3.5; p < 0.001) (Table 3, Fig. 4). Table 3Multivariable logistic regression identifying independent correlates of imaging-defined subclinical atherosclerosis.PredictorAdjusted OR95% CIp-valueAge (per year increase)1.041.02–1.06<0.001Female sex1.351.01–1.800.04BMI (per unit increase)1.071.03–1.11<0.001TSH >7 mIU/L1.71.20–2.300.002LDL-C > 160 mg/dL2.11.50–2.90<0.001hs-CRP >3 mg/L1.91.40–2.50<0.001Metabolic syndrome2.51.80–3.50<0.001 Multivariable logistic regression identifying independent correlates of imaging-defined subclinical atherosclerosis. Forest plot of independent correlates of imaging-defined subclinical atherosclerosis. Traditional cardiovascular risk factors, including smoking status, hypertension, diabetes mellitus, and lipid-lowering therapy, were examined in exploratory analyses but were not retained in the primary model in order to preserve model parsimony and reduce overlap with metabolic syndrome and related cardiometabolic covariates. No statistically significant interaction was observed between TSH >7 mIU/L and metabolic syndrome (p for interaction = 0.13). Subgroup findings: combined SCH severity and metabolic burden When SCH severity and metabolic burden coexisted, imaging risk was particularly pronounced. Participants with both TSH >7 mIU/L and metabolic syndrome demonstrated a higher prevalence of CAC and carotid abnormalities compared with those without metabolic syndrome. These findings suggest a high-risk subgroup characterized by combined endocrine and metabolic vulnerability. Discussion This cross-sectional study provides contemporary real-world evidence that a clinically meaningful proportion of patients with subclinical hypothyroidism (SCH) harbor objective imaging evidence of subclinical atherosclerosis. In a large, well-characterized cohort without established CV disease, nearly half demonstrated imaging-defined subclinical atherosclerosis (abnormal CAC and/or carotid ultrasound findings), supporting the concept that SCH may represent more than a biochemical “borderline” state in selected patients [25]. These findings align with European recommendations emphasizing individualized risk assessment in SCH rather than routine treatment for all patients [26] and reinforce prior evidence syntheses showing heterogeneity in CV risk across SCH populations [27], [28]. Our results further clarify the biologic and clinical profile associated with imaging-defined risk in SCH. The strongest independent correlates were atherogenic dyslipidemia (LDL-C > 160 mg/dL), systemic inflammation (hs-CRP >3 mg/L), higher TSH burden (>7 mIU/L), and coexisting metabolic syndrome—factors that plausibly represent converging pathways toward accelerated atherosclerosis. These observations are consistent with prior work indicating that SCH-related CV associations vary by age and baseline cardiometabolic risk [29] and with data supporting an adverse clustering of metabolic risk traits in SCH [30]. Importantly, prior longitudinal cohorts and meta-analyses have linked SCH—particularly at higher TSH levels—to heart failure events and ischemic outcomes, supporting the clinical relevance of the phenotypes captured in our imaging-based definition of risk [31], [32]. These findings should be interpreted as associative rather than causal. In particular, the cross-sectional design does not establish that SCH itself drives atherosclerosis progression, but rather that within SCH there exists a subgroup with a higher burden of imaging-detected vascular disease. A key strength of the present study is the use of complementary vascular imaging modalities as objective risk “endpoints.” CAC scoring and carotid ultrasound identify subclinical atherosclerosis beyond traditional risk factors, and CAC burden in particular has demonstrated strong event discrimination across diverse populations [33]. Similarly, carotid intima-media thickness and plaque presence reflect cumulative arterial injury and are independently associated with future CV events [34]. When integrated with established prevention frameworks, these imaging markers can refine treatment intensity—particularly for lipid-lowering—where guideline pathways explicitly recognize imaging and risk-enhancing factors to guide preventive pharmacotherapy [35]. Collectively, the observed prevalence of CAC >100 and carotid plaque in SCH supports a practical approach in which imaging is selectively deployed to identify high-risk individuals who would otherwise be misclassified as “intermediate” risk by conventional tools. Importantly, the composite endpoint used in this study reflects imaging-defined subclinical atherosclerosis rather than cardiovascular risk itself; accordingly, our analyses should be interpreted as identifying correlates of imaging-positive vascular burden rather than direct predictors of future clinical events. The interaction between SCH and metabolic syndrome in our cohort is clinically important and reinforces the need for integrated endocrine–cardiometabolic prevention strategies. SCH has been linked to higher rates of heart failure events in pooled individual participant analyses [36] and occurs frequently in populations with substantial baseline cardiometabolic risk [37]. In parallel, the overlap of SCH with type 2 diabetes and metabolic syndrome has been repeatedly demonstrated [38], [39], providing a plausible substrate for synergistic risk amplification. In our data, metabolic syndrome substantially increased the prevalence of imaging abnormalities, suggesting that SCH may function as a risk multiplier when combined with insulin resistance, adiposity, and inflammatory activation. This phenotype may represent the highest-yield subgroup for intensified prevention, including aggressive lipid lowering, weight management, and optimization of glycemic and blood pressure control. The therapeutic implications of these findings should be interpreted with appropriate caution. While observational studies have reported increased ischemic heart disease and mortality in SCH [40], expert reviews emphasize that benefit from levothyroxine is not uniform and is influenced by symptoms, age, TSH severity, antibody status, and competing risks [41], [42]. Current American Thyroid Association guidance supports treatment consideration in selected patients (e.g., higher TSH, symptoms, pregnancy planning, or high-risk features) [43], while broader evidence summaries continue to highlight uncertainty regarding long-term CV benefit of routine hormone replacement in mild SCH [44]. Notably, randomized evidence in older adults did not demonstrate symptomatic benefit from levothyroxine therapy [45], and a large meta-analysis similarly found no meaningful improvement in quality of life or thyroid-related symptoms across randomized trials [46]. Together, these data support a risk-based approach rather than automatic treatment—where the priority may shift toward aggressive modification of cardiometabolic risk drivers (lipids, inflammation, adiposity) and selective use of thyroid hormone therapy in appropriately enriched subgroups. From a prevention standpoint, our findings also support the use of CAC and carotid imaging as actionable tools to “upgrade” preventive intensity in SCH patients with clustered risk. The ACC/AHA primary prevention guideline explicitly recognizes CAC as a decision aid for statin allocation and overall risk refinement, particularly when clinical uncertainty exists [47]. In parallel, dedicated CAC reporting guidance provides standardized acquisition and interpretation frameworks, improving reproducibility and clinical implementation [48]. Contemporary reviews further emphasize CAC's strong prognostic value and its role in modern prevention workflows [49], while global CAC guidance documents have consolidated international recommendations for when and how CAC should be used to guide preventive therapies [50]. In this context, imaging-positive SCH patients—especially those with metabolic syndrome or elevated LDL-C—represent a rational target for intensified primary prevention strategies. This study has limitations. The cross-sectional design precludes causal inference and does not establish whether imaging abnormalities translate into higher prospective event rates in this specific SCH cohort. Residual confounding is possible, particularly from unmeasured lifestyle exposures. In addition, thyroid autoimmunity status and SCH duration were not incorporated, both of which may influence risk heterogeneity. Nevertheless, the study's strengths include its sizeable cohort, systematic imaging evaluation, and clinically pragmatic definition of imaging-defined subclinical atherosclerosis using established atherosclerosis measures. Second, the primary composite endpoint was defined using imaging markers of subclinical atherosclerosis rather than adjudicated cardiovascular outcomes, and therefore should not be interpreted as a direct measure of clinical cardiovascular risk. Third, residual confounding remains possible, including from lifestyle factors, smoking exposure, medication use, and other cardiometabolic variables that may not have been fully captured or modeled. Conclusion A substantial proportion of adults with subclinical hypothyroidism demonstrated imaging-defined subclinical atherosclerosis. Greater atherosclerotic burden was independently associated with LDL-C elevation, systemic inflammation, higher TSH burden, and metabolic syndrome. These findings support a more individualized cardiometabolic risk assessment strategy in SCH and provide a rationale for prospective studies to determine whether imaging-guided preventive interventions improve long-term outcomes. CRediT authorship contribution statement Arif Albulushi: Supervision. Murtadha S. Hasan: Data curation. Rayan S. Alazawi: Formal analysis. Maryam Al Sarmi: Investigation. Hajar Al-Mandhari: Methodology. Abdullah AlShaharli: Resources. Amjad S. Hasan: Software. Yaseen Al-Helli: Validation. Abdullah Allo: Visualization. Eslam Abdelazim: Methodology. Taghrid Taha: Formal analysis. Ahmed Sena: Conceptualization. Abdulhakim M. Alhazmi: Investigation. Lama S. Alfehaid: Writing – original draft. Consent to participate All participants provided written informed consent to take part in this study. Clinical trial number Not applicable. Consent for publication Not applicable. Ethical approval This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of the Royal Hospital, Muscat, Oman. Funding No external funding was received for this research. Declaration of competing interest The authors declare no conflicts of interest relevant to this work. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. References Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.